Amit D. Munshi

Director, President & Chief Executive Officer at Arena Pharmaceuticals, Inc.

Amit D. Munshi

Amit D. Munshi

Director, President & Chief Executive Officer at Arena Pharmaceuticals, Inc.

Overview
Career Highlights

Arena Pharmaceuticals, Inc.
Zalicus, Inc.
EPIRUS Biopharmaceuticals, Inc. (Inactive)

RelSci Relationships

3666

Number of Boards

15

Birthday

1968

Age

53

Relationships
RelSci Relationships are individuals Amit D. Munshi likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chairman of the Board, President & Chief Executive Officer at Kala Pharmaceuticals, Inc.

Relationship likelihood: Strong

Former Executive Chairman at Blackthorn Therapeutics, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Director at Oxeia Biopharmaceuticals, Inc.

Relationship likelihood: Strong

Venture Partner at Nextgen Venture Partners LLC

Relationship likelihood: Strong

Founding Partner at 5AM Venture Management LLC

Relationship likelihood: Strong

Chief Scientific Officer at Cerecor, Inc.

Relationship likelihood: Strong

Director, President & Chief Executive Officer at Aimmune Therapeutics, Inc.

Relationship likelihood: Strong

Robert C. & Nanette T. Packard Professor of Law at University of Southern California Gould School of Law

Relationship likelihood: Strong

Former Chief Executive Officer & Director at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder at Cytrellis Biosystems, Inc.

Relationship likelihood: Strong

Paths to Amit D. Munshi
Potential Connections via
Relationship Science
You
Amit D. Munshi
Director, President & Chief Executive Officer at Arena Pharmaceuticals, Inc.
Education
BA in History
Class of 1990

The University of California, Riverside (UCR or UC Riverside), is a public research university and one of the 10 general campuses of the University of California system. The main campus sits on 1,900 acres (769 ha) in a suburban district of Riverside, California, United States, with a branch campus of 20 acres (8 ha) in Palm Desert. Founded in 1907 as the UC Citrus Experiment Station, Riverside, pioneered research in biological pest control and the use of growth regulators responsible for extending the citrus growing season in California from four to nine months. Some of the world's most important research collections on citrus diversity and entomology, as well as science fiction and photography, are located at Riverside.

M.B.A

The Peter F. Drucker and Masatoshi Ito Graduate School of Management, or more commonly, the Drucker School of Management, is the business school of Claremont Graduate University, which is a member of the Claremont Colleges. The school is named in honor of Peter Drucker, who taught management at the school for over 30 years.

Career History
Director, President & Chief Executive Officer
2016 - Current

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Co-Founder
2014 - Current

Oxeia Biopharmaceuticals, Inc. is a private company headquartered in San Diego, CA, that manufactures pharmaceutical products. The firm was founded by Amit Dilip Munshi. Michael Wyand is the current CEO, occupying that position since 2017.The company says this about itself: Oxeia Biopharmaceuticals, Inc. is a privately held clinical stage bio technology company headquartered in San Diego, CA. The company is focused on developing treatments for concussions and other acute neurotrauma conditions. Oxeia’s lead program, OXE-103, uniquely targets the metabolic dysfunction and subsequent neurotrauma underlying acute concussion pathophysiology. Oxeia anticipates initiating Phase 2 studies for OXE-103 in concussion and additional neurological indications in early 2018. The program has maintained a strong safety profile across nine previous clinical studies totaling 345 patients.

Director, President & Chief Executive Officer
2014 - Prior

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.

Boards & Committees
Director, President & Chief Executive Officer
2014 - Prior

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. Zalicus has a portfolio of proprietary clinical-stage product candidates targeting pain, including Z160, an N-type calcium channel blocker for chronic neuropathic pain and Z944, a T-type calcium channel blocker for acute and inflammatory pain. We have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Zalicus applies its expertise in the discovery and development of selective ion channel modulators and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease.

Member, Board of Directors
Prior

Epirus is a biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies. Epirus’s strategy addresses the fragmented and complex global regulatory and commercial landscape for biosimilars and leverages market insights with close local collaborations to gain competitive advantages in target markets.

Director
Prior
Transactions
Details Hidden

Oxeia Biopharmaceuticals, Inc. raised money in a private placement transaction

Investments
Details Hidden

Kythera Biopharmaceuticals LLC operates as a clinical-stage biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The company was founded by Jay Edward Birnbaum, Amit D. Munshi, Nathaniel Eames David, and Keith R. Leonard, Jr. on June 3, 2004 and is headquartered in Westlake, CA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Amit D. Munshi. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Amit D. Munshi's profile does not indicate a business or promotional relationship of any kind between RelSci and Amit D. Munshi.